<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340312</url>
  </required_header>
  <id_info>
    <org_study_id>490390</org_study_id>
    <nct_id>NCT02340312</nct_id>
  </id_info>
  <brief_title>Functional Dyspepsia Microbiome Study</brief_title>
  <official_title>Evaluation of the Duodenal Microbiome in Pediatric Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent abdominal pain has long been acknowledged to be the most common chronic pain&#xD;
      entities in children. The purpose of this study is to describe the microbiome in children&#xD;
      with FD and to explore relationships between the microbiome and postprandial distress&#xD;
      syndrome, anxiety scores, and mucosal biomarkers or anxiety. The specific goals of this study&#xD;
      are to: 1) Determine the frequencies and relative proportions for specific bacteria or&#xD;
      bacteria phyla in children with FD in both duodenal mucosal specimens and stool samples. 2)&#xD;
      Determine if the frequencies or proportions of specific bacteria or bacteria phyla differ&#xD;
      between children with and without PDS. 3) Determine bi-variate correlations between&#xD;
      bacteria/phyla frequency, bacteria/phyla proportions, anxiety scores, and mucosal biomarkers,&#xD;
      respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the current study is to describe the microbiome in children with FD and to&#xD;
      explore relationships between the microbiome and postprandial distress syndrome, anxiety&#xD;
      scores, and mucosal biomarkers or anxiety.&#xD;
&#xD;
      SPECIFIC AIMS&#xD;
&#xD;
        1. To determine the frequencies and relative proportions for specific bacteria or bacteria&#xD;
           phyla in children with FD in both duodenal mucosal specimens and stool samples.&#xD;
&#xD;
        2. To determine if the frequencies or proportions of specific bacteria or bacteria phyla&#xD;
           differ between children with and without PDS.&#xD;
&#xD;
        3. To determine bi-variate correlations between bacteria/phyla frequency, bacteria/ phyla&#xD;
           proportion, anxiety scores, and mucosal biomarkers, respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome Analysis</measure>
    <time_frame>within 12 months from collection</time_frame>
    <description>Fecal samples and 8 mucosal biopsies (descending duodenum) will be obtained from each subject. Samples will be processed and DNA isolated per standard lab techniques.16S rDNA sequence analysis of microbial communities within patient samples will be analyzed utilizing our HiSeq 1500 rapid run technologies. We will perform 2 X 150 bp paired end sequencing which will give exceptional coverage (reads &gt; 30,000). We will sequence the V4 region of 16s RNA (E. coli 515-806), which is the method optimized for Illumina HiSeq 1500 currently. We will also sequence simultaneously the V3 region of 16s RNA to provide a dual-control analysis of samples. Confirmatory PCR will be employed when appropriate. Data will be reported as total counts for each identified bacterial species.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Cell Density</measure>
    <time_frame>within 12 months from collection</time_frame>
    <description>Routine histology slides previously stained with hematoxylin and eosin will be utilized for determination of eosinophil density.&#xD;
IHC techniques will be utilized for determination of mast cell density. Serial 3-μm paraffin sections will be air dried and heat fixed on slides. The sections will be deparaffinized with xylene and iodine and rehydrated in a graded series of alcohol. Utilizing tryptase monoclonal mouse antihuman mast cell tryptase antibody (clone AA1, Dako, Carpinteria, CA), sections will be stained on an automated Dako Autostainer 3400 using Dako's LSAB+ kit with streptavidin conjugated to horseradish peroxidase.&#xD;
To determine density for each cell type, the entire specimen will be scanned to determine the subjective area of greatest involvement. Density will be determined by counting cells within 5 consecutive high-power fields (400X magnification). Peak and mean cell densities expressed as cells/hpf will be determined. This will be completed before study end.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunohistochemistry (IHC)</measure>
    <time_frame>within 12 months from collection</time_frame>
    <description>IHC staining will be performed and may include DCLK1, BDNF, TRPV1, and/or CRH-R1, respectively, depending on the results of an on-going pilot study. Staining intensity will be evaluated in a blinded fashion by a pathologist to assign scores for average IHC signal intensity (i.e. 0= none, 1= mild, 2= moderate, and 3= strong) as well as the percentage of tissue cells or fibers showing positive immunoreactivity. A sem-quantitative scoring system will be applied in which the final immunoreactive score will equal the product of the percentage of positive cells times the average staining intensity. Percentage of positive cells or fibers will be graded as follows: 0= negative-10%, 1= 11-33%, 2= 33-66%, and 3= &gt; 67%. Immunoreactivity will be considered positive when the combined score ranges between 2-6 and negative with a score of 0-1. Other IHC stains may be performed should they become relevant as indicated by the literature. This will be performed before study end.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-scores for the BASC will be collected as part of this study on the Data Collection Form.</measure>
    <time_frame>within 6 months from completion</time_frame>
    <description>This information is used to assess psychosocial information from the patient.This will be collected and recorded before study end.</description>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Functional Dyspepsia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EGD</intervention_name>
    <description>In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of Stool Specimens</intervention_name>
    <description>We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of .5 aggregate of doudenal tissue. Collection of stool samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children and adolecents ages 8 to 17 inclusive that have been diagonsed with functional&#xD;
        dyspepsia and are scheduled to have a EGD with biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of FD as determined by the GI physician in accordance with Rome III criteria&#xD;
&#xD;
          -  Age 8-17 years inclusive&#xD;
&#xD;
          -  Scheduled for upper endoscopy as part of routine care after failing to respond to acid&#xD;
             suppression therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of oral antibiotic or probiotic within 8 weeks prior to enrollment&#xD;
&#xD;
          -  Use of systemic steroid or immunomodulating drug within 8 weeks of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A Friesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hyams JS, Davis P, Sylvester FA, Zeiter DK, Justinich CJ, Lerer T. Dyspepsia in children and adolescents: a prospective study. J Pediatr Gastroenterol Nutr. 2000 Apr;30(4):413-8.</citation>
    <PMID>10776953</PMID>
  </reference>
  <reference>
    <citation>Youssef NN, Murphy TG, Langseder AL, Rosh JR. Quality of life for children with functional abdominal pain: a comparison study of patients' and parents' perceptions. Pediatrics. 2006 Jan;117(1):54-9.</citation>
    <PMID>16396860</PMID>
  </reference>
  <reference>
    <citation>Walker LS, Garber J, Van Slyke DA, Greene JW. Long-term health outcomes in patients with recurrent abdominal pain. J Pediatr Psychol. 1995 Apr;20(2):233-45.</citation>
    <PMID>7760222</PMID>
  </reference>
  <reference>
    <citation>Gieteling MJ, Bierma-Zeinstra SM, Passchier J, Berger MY. Prognosis of chronic or recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr. 2008 Sep;47(3):316-26. doi: 10.1097/MPG.0b013e31815bc1c1.</citation>
    <PMID>18728528</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Friesen CA, Danda CE, Andre L, Welchert E, Lavenbarg T, Cocjin JT, Hyman PE. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):291-5.</citation>
    <PMID>16131983</PMID>
  </reference>
  <reference>
    <citation>Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006 Apr;130(5):1527-37.</citation>
    <PMID>16678566</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.</citation>
    <PMID>20479684</PMID>
  </reference>
  <reference>
    <citation>Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol. 2011 Dec 7;2:94. doi: 10.3389/fphys.2011.00094. eCollection 2011.</citation>
    <PMID>22162969</PMID>
  </reference>
  <reference>
    <citation>Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011 Dec;62(6):591-9. Review.</citation>
    <PMID>22314561</PMID>
  </reference>
  <reference>
    <citation>Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011 Mar;23(3):255-64, e119. doi: 10.1111/j.1365-2982.2010.01620.x. Epub 2010 Nov 5.</citation>
    <PMID>21054680</PMID>
  </reference>
  <reference>
    <citation>Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009 Mar 19;1(1):6. doi: 10.1186/1757-4749-1-6.</citation>
    <PMID>19338686</PMID>
  </reference>
  <reference>
    <citation>Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011 Mar;23(3):187-92. doi: 10.1111/j.1365-2982.2010.01664.x.</citation>
    <PMID>21303428</PMID>
  </reference>
  <reference>
    <citation>Lyte M, Li W, Opitz N, Gaykema RP, Goehler LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav. 2006 Oct 30;89(3):350-7. Epub 2006 Aug 2.</citation>
    <PMID>16887154</PMID>
  </reference>
  <reference>
    <citation>Gabel LA, Marin I, LoTurco JJ, Che A, Murphy C, Manglani M, Kass S. Mutation of the dyslexia-associated gene Dcdc2 impairs LTM and visuo-spatial performance in mice. Genes Brain Behav. 2011 Nov;10(8):868-75. doi: 10.1111/j.1601-183X.2011.00727.x. Epub 2011 Oct 19.</citation>
    <PMID>21883923</PMID>
  </reference>
  <reference>
    <citation>Li Y, Ji YJ, Jiang H, Liu DX, Zhang Q, Fan SJ, Pan F. Effects of unpredictable chronic stress on behavior and brain-derived neurotrophic factor expression in CA3 subfield and dentate gyrus of the hippocampus in different aged rats. Chin Med J (Engl). 2009 Jul 5;122(13):1564-9.</citation>
    <PMID>19719949</PMID>
  </reference>
  <reference>
    <citation>Shi SS, Shao SH, Yuan BP, Pan F, Li ZL. Acute stress and chronic stress change brain-derived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus. Yonsei Med J. 2010 Sep;51(5):661-71. doi: 10.3349/ymj.2010.51.5.661.</citation>
    <PMID>20635439</PMID>
  </reference>
  <reference>
    <citation>Yang J, Yu Y, Yu H, Zuo X, Liu C, Gao L, Chen ZY, Li Y. The role of brain-derived neurotrophic factor in experimental inflammation of mouse gut. Eur J Pain. 2010 Jul;14(6):574-9. doi: 10.1016/j.ejpain.2009.10.007. Epub 2009 Nov 20.</citation>
    <PMID>19932037</PMID>
  </reference>
  <reference>
    <citation>Yu YB, Zuo XL, Zhao QJ, Chen FX, Yang J, Dong YY, Wang P, Li YQ. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut. 2012 May;61(5):685-94. doi: 10.1136/gutjnl-2011-300265. Epub 2011 Oct 13.</citation>
    <PMID>21997550</PMID>
  </reference>
  <reference>
    <citation>Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008 Jul;57(7):923-9. doi: 10.1136/gut.2007.138982. Epub 2008 Feb 5.</citation>
    <PMID>18252749</PMID>
  </reference>
  <reference>
    <citation>Miranda A, Nordstrom E, Mannem A, Smith C, Banerjee B, Sengupta JN. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. Neuroscience. 2007 Sep 21;148(4):1021-32. Epub 2007 Aug 23.</citation>
    <PMID>17719181</PMID>
  </reference>
  <reference>
    <citation>Matsumoto K, Lo MW, Hosoya T, Tashima K, Takayama H, Murayama T, Horie S. Experimental colitis alters expression of 5-HT receptors and transient receptor potential vanilloid 1 leading to visceral hypersensitivity in mice. Lab Invest. 2012 May;92(5):769-82. doi: 10.1038/labinvest.2012.14. Epub 2012 Feb 13.</citation>
    <PMID>22330338</PMID>
  </reference>
  <reference>
    <citation>Yang CQ, Wei YY, Zhong CJ, Duan LP. Essential role of mast cells in the visceral hyperalgesia induced by T. spiralis infection and stress in rats. Mediators Inflamm. 2012;2012:294070. doi: 10.1155/2012/294070. Epub 2012 Mar 7.</citation>
    <PMID>22529522</PMID>
  </reference>
  <reference>
    <citation>Akbar A, Yiangou Y, Facer P, Brydon WG, Walters JR, Anand P, Ghosh S. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010 Jun;59(6):767-74. doi: 10.1136/gut.2009.194449.</citation>
    <PMID>20551462</PMID>
  </reference>
  <reference>
    <citation>Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut. 1998 Jun;42(6):845-9.</citation>
    <PMID>9691924</PMID>
  </reference>
  <reference>
    <citation>Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006 Feb;130(2):304-11.</citation>
    <PMID>16472586</PMID>
  </reference>
  <reference>
    <citation>Posserud I, Agerforz P, Ekman R, Björnsson ES, Abrahamsson H, Simrén M. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut. 2004 Aug;53(8):1102-8.</citation>
    <PMID>15247175</PMID>
  </reference>
  <reference>
    <citation>Böhmelt AH, Nater UM, Franke S, Hellhammer DH, Ehlert U. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med. 2005 Mar-Apr;67(2):288-94.</citation>
    <PMID>15784796</PMID>
  </reference>
  <reference>
    <citation>Dickhaus B, Mayer EA, Firooz N, Stains J, Conde F, Olivas TI, Fass R, Chang L, Mayer M, Naliboff BD. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol. 2003 Jan;98(1):135-43.</citation>
    <PMID>12526949</PMID>
  </reference>
  <reference>
    <citation>La JH, Sung TS, Kim HJ, Kim TW, Kang TM, Yang IS. Peripheral corticotropin releasing hormone mediates post-inflammatory visceral hypersensitivity in rats. World J Gastroenterol. 2008 Feb 7;14(5):731-6.</citation>
    <PMID>18205263</PMID>
  </reference>
  <reference>
    <citation>Wood JD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology. 2004 Aug;127(2):635-57. Review.</citation>
    <PMID>15300595</PMID>
  </reference>
  <reference>
    <citation>He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004 Feb 1;10(3):309-18. Review.</citation>
    <PMID>14760748</PMID>
  </reference>
  <reference>
    <citation>Hall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9.</citation>
    <PMID>15017654</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Lin Z, Singh M, Singh V, Schurman JV, Burchell N, Cocjin JT, McCallum RW. Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008 Oct;53(10):2634-40. doi: 10.1007/s10620-008-0207-0. Epub 2008 Mar 5.</citation>
    <PMID>18320315</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Lin Z, Hyman PE, Andre L, Welchert E, Schurman JV, Cocjin JT, Burchell N, Pulliam S, Moore A, Lavenbarg T, McCallum RW. Electrogastrography in pediatric functional dyspepsia: relationship to gastric emptying and symptom severity. J Pediatr Gastroenterol Nutr. 2006 Mar;42(3):265-9.</citation>
    <PMID>16540794</PMID>
  </reference>
  <reference>
    <citation>Santos J, Saperas E, Nogueiras C, Mourelle M, Antolín M, Cadahia A, Malagelada JR. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998 Apr;114(4):640-8.</citation>
    <PMID>9516384</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Sandridge L, Andre L, Roberts CC, Abdel-Rahman SM. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006 Mar;45(2):143-7.</citation>
    <PMID>16528434</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agréus L. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83. Epub 2007 Aug 7.</citation>
    <PMID>17686660</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Andre L, Garola R, Hodge C, Roberts C. Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):329-33.</citation>
    <PMID>12352522</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):343-51.</citation>
    <PMID>15076638</PMID>
  </reference>
  <reference>
    <citation>Chrousos GP. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol. 2000 Nov;106(5 Suppl):S275-91. Review.</citation>
    <PMID>11080744</PMID>
  </reference>
  <reference>
    <citation>Kokkotou E, Torres D, Moss AC, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol. 2006 Sep 1;177(5):3355-61.</citation>
    <PMID>16920976</PMID>
  </reference>
  <reference>
    <citation>Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. 2010 Apr 16;7:27. doi: 10.1186/1742-2094-7-27. Review.</citation>
    <PMID>20398373</PMID>
  </reference>
  <reference>
    <citation>White FA, Feldman P, Miller RJ. Chemokine signaling and the management of neuropathic pain. Mol Interv. 2009 Aug;9(4):188-95. doi: 10.1124/mi.9.4.7. Review.</citation>
    <PMID>19720751</PMID>
  </reference>
  <reference>
    <citation>Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010 Oct 1;26(19):2460-1. doi: 10.1093/bioinformatics/btq461. Epub 2010 Aug 12.</citation>
    <PMID>20709691</PMID>
  </reference>
  <reference>
    <citation>DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006 Jul;72(7):5069-72.</citation>
    <PMID>16820507</PMID>
  </reference>
  <reference>
    <citation>Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics. 2010 Jan 15;26(2):266-7. doi: 10.1093/bioinformatics/btp636. Epub 2009 Nov 13.</citation>
    <PMID>19914921</PMID>
  </reference>
  <reference>
    <citation>Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol. 2009 Jul;26(7):1641-50. doi: 10.1093/molbev/msp077. Epub 2009 Apr 17.</citation>
    <PMID>19377059</PMID>
  </reference>
  <reference>
    <citation>Helmus MR, Bland TJ, Williams CK, Ives AR. Phylogenetic measures of biodiversity. Am Nat. 2007 Mar;169(3):E68-83. doi: 10.1086/511334. Epub 2007 Jan 17.</citation>
    <PMID>17230400</PMID>
  </reference>
  <reference>
    <citation>Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective distance metric for microbial community comparison. ISME J. 2011 Feb;5(2):169-72. doi: 10.1038/ismej.2010.133. Epub 2010 Sep 9.</citation>
    <PMID>20827291</PMID>
  </reference>
  <reference>
    <citation>Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005 Dec;71(12):8228-35.</citation>
    <PMID>16332807</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Schurman JV, Qadeer A, Andre L, Welchert E, Cocjin J. Relationship between mucosal eosinophils and anxiety in pediatric dyspepsia. Gastroenterology 2005; 129:A-158</citation>
  </reference>
  <reference>
    <citation>Carpenter S. That gut feeling. Monitor on Psychol 2012; 43:51-55</citation>
  </reference>
  <reference>
    <citation>Bienenstock J, Collins S. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: psycho-neuroimmunology and the intestinal microbiota: clinical observations and basic mechanisms. Clin Exp Immunol. 2010 Apr;160(1):85-91. doi: 10.1111/j.1365-2249.2010.04124.x.</citation>
    <PMID>20415856</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Craig A. Friesen, MD</investigator_full_name>
    <investigator_title>M.D. Divison Cheif Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

